GEH 120714

Drug Profile

GEH 120714

Alternative Names: [18F] GEH120714; [18F]-GE180; flutriciclamide [18F]; GE 180; GEH120714

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Imaging agents; Radioisotopes
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease; Multiple sclerosis
  • No development reported Neurological disorders

Most Recent Events

  • 20 Jul 2017 Efficacy data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
  • 08 Mar 2017 CTP push 237990 (NCT01738347) - trial doesn't mention USA as trial site; removed USA from dev, added trial completion and ADS
  • 23 Feb 2017 GEH 120714 is still in phase I development for Multiple sclerosis (Diagnosis) in Canada (NCT01738347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top